#United States #San Diego #Robbins LLP #Savara Inc. #MOLBREEVI

Robbins LLP Files Class Action Lawsuit Against Savara Inc. for Misleading Investors

In a significant move, Robbins LLP has announced a class action lawsuit against Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases. This legal action, which affects investors who acquired Savara shares between March 7, 2024, and May 23, 2025, stems from allegations that the company misled its shareholders regarding the viability of its lead drug candidate, MOLBREEVI.

Background of Savara Inc.

Savara Inc. focuses on developing innovative therapies for rare respiratory conditions. Its lead product, MOLBREEVI (molgramostim), is an inhaled colony-stimulating factor that has garnered attention for its potential benefits in treating specific diseases. Investors were optimistic about the clinical and market potential of this product, which is why the recent allegations have shaken confidence among Savara's stockholders.

The Allegations

According to the complaint filed by Robbins LLP, the company failed to disclose critical information about the Biologics License Application (BLA) for MOLBREEVI. Specifically, it was reported that:

• - The BLA lacked adequate information on the drug's chemistry, manufacturing, and controls.
• - Consequently, approval from the FDA for the BLA in its present form was deemed unlikely.
• - This lack of transparency delayed Savara's ability to complete its BLA submission within the projected timeframe, misleading investors regarding the company's operational progress.

On May 27, 2025, Savara issued a press release revealing that it had received a refusal to file (RTF) letter from the FDA concerning the MOLBREEVI application. This letter stated that the submission was not sufficiently complete for a substantive review, prompting a significant decline in Savara's stock price of 31.69%, closing at $1.94 per share the same day.

Impact on Investors

The fallout from this disclosure has left investors reeling, as many had placed their faith and resources in the company based on its previous announcements. Robbins LLP is now rallying for shareholders to join the class action lawsuit. Shareholders interested in acting as lead plaintiff are encouraged to reach out to the firm.

A lead plaintiff plays a pivotal role in guiding the litigation process and representing the class members. Importantly, investors can opt not to participate in the lawsuit but remain eligible for recovery should the case yield a favorable outcome.

Robbins LLP works on a contingency fee basis, meaning shareholders do not incur any costs unless the lawsuit is successful. This structure encourages broader participation from those affected by the alleged misconduct.

About Robbins LLP

Established in 2002, Robbins LLP has gained recognition for its advocacy in shareholder rights litigation. The firm has consistently pursued actions to help investors recover losses, improve governance practices, and hold corporate executives accountable when necessary.

In light of Savara’s recent challenges, investors are encouraged to remain vigilant and proactive. Those seeking updates on this case or interested in staying informed about corporate governance issues can sign up for the firm's Stock Watch notifications.

For shareholders affected by Savara Inc.'s actions, this class action represents an opportunity for recourse. To learn more about participating in the lawsuit or gaining further insight into the implications, potential plaintiffs are advised to contact Robbins LLP directly through the provided channels.

This situation underlines the importance of transparency and accountability in the pharmaceutical industry, where the health of investors can markedly intertwine with the ethical considerations of clinical development.